Thomas Herzog, MD | Authors


Dr. Thomas Herzog on the Cautions of Interval Debulking Surgery in Ovarian Cancer

November 25, 2015

Thomas Herzog, MD, on the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.

Dr. Thomas Herzog on Who Benefits From Neoadjuvant Therapies

November 06, 2015

Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.